AU2018337933A1 - Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults - Google Patents

Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults Download PDF

Info

Publication number
AU2018337933A1
AU2018337933A1 AU2018337933A AU2018337933A AU2018337933A1 AU 2018337933 A1 AU2018337933 A1 AU 2018337933A1 AU 2018337933 A AU2018337933 A AU 2018337933A AU 2018337933 A AU2018337933 A AU 2018337933A AU 2018337933 A1 AU2018337933 A1 AU 2018337933A1
Authority
AU
Australia
Prior art keywords
cbd
effective amount
star
seizures
seizure frequency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018337933A
Other languages
English (en)
Inventor
Donna Gutterman
John MESSENHEIMER
Terri Sebree
Ted Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynerba Pharmaceuticals Inc
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of AU2018337933A1 publication Critical patent/AU2018337933A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018337933A 2017-09-19 2018-09-18 Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults Abandoned AU2018337933A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762560446P 2017-09-19 2017-09-19
US62/560,446 2017-09-19
US201762593575P 2017-12-01 2017-12-01
US62/593,575 2017-12-01
US201862613160P 2018-01-03 2018-01-03
US62/613,160 2018-01-03
US201862652995P 2018-04-05 2018-04-05
US62/652,995 2018-04-05
US201862660198P 2018-04-19 2018-04-19
US62/660,198 2018-04-19
PCT/IB2018/057189 WO2019058261A1 (en) 2017-09-19 2018-09-18 TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS

Publications (1)

Publication Number Publication Date
AU2018337933A1 true AU2018337933A1 (en) 2020-03-12

Family

ID=63762572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018337933A Abandoned AU2018337933A1 (en) 2017-09-19 2018-09-18 Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults

Country Status (11)

Country Link
US (4) US20190083388A1 (https=)
EP (1) EP3684411A1 (https=)
JP (2) JP2020534362A (https=)
KR (1) KR20200055067A (https=)
AU (1) AU2018337933A1 (https=)
BR (1) BR112020004947A2 (https=)
CA (1) CA3075719A1 (https=)
IL (2) IL301910A (https=)
JO (1) JOP20200045A1 (https=)
MX (2) MX2020003004A (https=)
WO (1) WO2019058261A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733156A1 (de) * 2019-05-02 2020-11-04 Gábor Fóti C.b.d.m therapie
CN114401713A (zh) * 2019-09-17 2022-04-26 Zyne制药公司 在发育性和癫痫性脑病中的行为损伤的治疗
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
CA3155176A1 (en) * 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
MX2023000314A (es) * 2020-08-17 2023-02-22 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas de cannabinoides.
JP2023552390A (ja) * 2020-12-03 2023-12-15 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 難治性発作の治療
CN117479930A (zh) * 2021-04-08 2024-01-30 长矛治疗股份有限公司 用于治疗癫痫发作病症的药物组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
JP2020534362A (ja) 2020-11-26
MX2020003004A (es) 2020-11-06
US20250213465A1 (en) 2025-07-03
BR112020004947A2 (pt) 2020-09-15
JP7650929B2 (ja) 2025-03-25
WO2019058261A1 (en) 2019-03-28
IL272818A (en) 2020-04-30
US20190083388A1 (en) 2019-03-21
MX2024002904A (es) 2024-04-04
KR20200055067A (ko) 2020-05-20
JP2023171776A (ja) 2023-12-05
CA3075719A1 (en) 2019-03-28
US20210030665A1 (en) 2021-02-04
EP3684411A1 (en) 2020-07-29
US20250302734A1 (en) 2025-10-02
WO2019058261A9 (en) 2019-07-04
IL301910A (en) 2023-06-01
JOP20200045A1 (ar) 2020-02-27

Similar Documents

Publication Publication Date Title
US20250302734A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP7590803B2 (ja) 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
Landen et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression
AU2023233141B2 (en) Method of treatment with tradipitant
AU2016255707A1 (en) Uses of cannabidiol for treatment of infantile spasms
JP7570924B2 (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
US4590213A (en) Anti-anxiety method
US20240009210A1 (en) Cannabidiol for the Treatment of Refractory Seizures
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
US20230000793A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
KR20240093852A (ko) 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료
WO2018051355A1 (en) Tamoxifen or tamoxifen in combination with arginine/citrulline for the use in the treatment of muscular dystrophy
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
KR20230137404A (ko) Cbd를 사용한 수면 무호흡증의 치료
JP7840873B2 (ja) うつ病の治療方法
Turovskaia et al. FRI0537 Neurophysiological data in patients with chronic pain in knee osteoarthritis
US20110245212A1 (en) Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
EA044821B1 (ru) Способ увеличения биологической доступности и степени воздействия активатора потенциал-зависимых калиевых каналов
JPH04230675A (ja) 不安の障害の処置剤
Prescott Tiagabine offers effective seizure control

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted